Patient Profiles and Outcomes in Endometriosis with Malignant or Borderline Ovarian Tumors: Insights from an ESGO Designated Center of Excellence - Top-Institutions - MDSpire

Patient Profiles and Outcomes in Endometriosis with Malignant or Borderline Ovarian Tumors: Insights from an ESGO Designated Center of Excellence

  • By

  • Maximilian Heinz Beck

  • Paul Kordowitzki

  • Eva Roser

  • Anna Trelinska-Finger

  • Emily Schoof

  • Lukas Chinczewski

  • Sylvia Mechsner

  • Jalid Sehouli

  • April 16, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Gynecologic Oncology
    • Molecular Oncology
    • Pathology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Gynecologic Oncology
    • Cancer Genomics
    • Translational Research

  • #3

    European Institute of Oncology (IEO)
    European Institute of Oncology (IEO)

    Milan, Lombardy

    Key Differentiators

    • Gynecologic Oncology
    • Molecular Pathology
    • Endometriosis Research

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Gynecologic Oncology
    • Reproductive Endocrinology
    • Cancer Biology

  • #5

    Dana-Farber Cancer Institute / Brigham and Women’s Hospital
    Dana-Farber Cancer Institute / Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Gynecologic Oncology
    • Cancer Genetics
    • Molecular Oncology

Original Source(s)

Patient Profiles and Outcomes in Endometriosis with Malignant or Borderline Ovarian Tumors: Insights from an ESGO Designated Center of Excellence

  • by Maximilian Heinz Beck, Paul Kordowitzki, Eva Roser, Anna Trelinska-Finger, Emily Schoof, Lukas Chinczewski, Sylvia Mechsner, Jalid Sehouli

  • April 16, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review